Skip to main content
Clinical Trials/NCT01464398
NCT01464398CompletedNot Applicable

Stress Reduction for PCOS and Non-PCOS Women

Milton S. Hershey Medical Center1 site in 1 country86 target enrollmentStarted: November 1, 2011Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
86
Locations
1
Primary Endpoint
Change from Baseline in Toronto Mindfulness Scale at 8 weeks

Study Overview

Brief Summary

The purpose of this study is to determine the effects of stress reduction on glucose, blood pressure, quality of life and overall health and well-being in overweight or obese women, either with Polycystic Ovary Syndrome (PCOS) or without PCOS (non-PCOS). Stress reduction treatment sessions will include one or more of the following activities: breathing exercises, meditation, stretching exercises or health education activities.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Women, age 18 years or older
  • •Body mass index (BMI) ≥ 25 kg/m2 (overweight or obese)

Exclusion Criteria

  • •Current pregnancy
  • •Secondary causes of hyperandrogenemia, such as known or suspected androgen secreting tumors, Cushing's syndrome, or hyperprolactinemia (prolactin >30)
  • •Untreated hypothyroidism or hyperthyroidism (defined as TSH <0.2 or >5.5 mIU/mL)
  • •Severe active neuropsychological disorder such as psychosis or suicidal ideation
  • •Severe untreated depression or anxiety. Women with severe depression or anxiety will be allowed to participate if they are under the care of a mental health specialist as long as they have permission to do so from their mental health specialist and will continue to follow-up with their mental health specialist during the study.
  • •History of an inpatient admission for psychiatric disorder within the past two years
  • •Active alcohol or drug abuse
  • •Inability to read, speak or write English
  • •Inability to commit to the intervention and follow-up
  • •Current enrollment in a stress reduction program
  • •Mindfulness practice within the past 6 months (regular formal practice at least once a week)
  • •Current enrollment in other investigative studies
  • •Type 1 diabetes

Arms & Interventions

Stress reduction

Active Comparator

Mindfulness-based stress reduction

Intervention: Stress reduction (Behavioral)

Stress reduction with Health education

Active Comparator

General stress management and health education

Intervention: Stress reduction with Health education (Behavioral)

Outcomes

Primary Outcomes

Change from Baseline in Toronto Mindfulness Scale at 8 weeks

Time Frame: baseline and 8 weeks

Secondary Outcomes

  • Change from Baseline in Hemoglobin A1c at 16 weeks(baseline and 16 weeks)
  • Change from Baseline in Mean Arterial Pressure at 16 weeks(baseline and 16 weeks)
  • Change from Baseline in Brief Symptom Inventory-18 at 16 weeks(baseline and 16 weeks)
  • Change from Baseline in Toronto Mindfulness Scale at 16 weeks(baseline and 16 weeks)
  • Change from Baseline in SF-36 at 16 weeks(baseline and 16 weeks)
  • Change from Baseline in Mean Arterial Pressure at 8 weeks(baseline and 8 weeks)
  • Change from Baseline in SF-36 at 8 weeks(baseline and 8 weeks)
  • Change from Baseline in Brief Symptom Inventory-18 at 8 weeks(baseline and 8 weeks)
  • Change from Baseline in Hemoglobin A1c at 8 weeks(baseline and 8 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Nazia Raja-Khan

M.D., Assistant Professor of Medicine, Division of Endocrinology, Diabetes, and Metabolism

Milton S. Hershey Medical Center

Study Sites (1)

Loading locations...

Similar Trials